PDMR Dealing

RNS Number : 0850J
Oncimmune Holdings PLC
18 December 2020
 

Oncimmune Holdings plc

 

("Oncimmune" or the "Company")

 

PDMR Dealing

 

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, has been notified that Adam Hill, PDMR and Chief Executive Officer, has purchased 5,764 ordinary shares of £0.01 each in the Company ("Ordinary Shares") for £1.7348 per share on 17 December 2020.

 

Following this transaction, Adam has a total interest in the Company of 3,537,539 Ordinary Shares, representing approximately 5.6 per cent of the Company's issued Ordinary Share capital.

 

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 


Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Dr Adam Mark Hill

2

 

Reason for the notification

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Oncimmune Holdings plc

b)

 

LEI

213800HCYIWT6YPI1I02 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of £0.01 each

 



Identification code

ISIN: GB00BYQ94H38



b)

 

Nature of the transaction

 

Purchase of shares

c)

 

Price(s) and volume(s)







Price

Volume




£1.7348

5,764







d)

 

Aggregated information




- Aggregated volume

Same as above



- Price




e)

 

Date of the transaction

 

17 December 2020

f)

 

Place of the transaction

London stock exchange, AIM

 

For further information:

 

Oncimmune Holdings plc

Ron Kirschner, General Counsel and Company Secretary

contact@oncimmune.com  

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKKOBNFBDDPBD
UK 100